Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920686 · ClinicalTrials.gov registry record · Phase 2
Study of NXN 188 for the Treatment of Migraine With Aura
A Phase 2 study, sponsored by NeurAxon.
- Completed
- Registry status
- Phase 2
- Development phase
- 239
- Enrollment target
NCT00920686 is a Phase 2 study that has completed, run by NeurAxon. The registered enrollment target is 239 participants.
The verdict
NCT00920686, a Phase 2 study, has completed, sponsored by NeurAxon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 239 participants
- Enrollment target
Study Summary
NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura.
Interventions
- DRUG placebo
- DRUG NXN-188
- DRUG sumatriptan succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00920686
The ClinicalTrials.gov registry entry for NCT00920686 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeurAxon, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00920686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00920686 about?
NCT00920686 is a clinical study titled "Study of NXN 188 for the Treatment of Migraine With Aura". NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura.
What is the current status of trial NCT00920686?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 239 participants. The study started on 2009-06. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00920686?
The interventions under investigation include: placebo (DRUG), NXN-188 (DRUG), sumatriptan succinate (DRUG).
Who is sponsoring clinical trial NCT00920686?
This trial is sponsored by NeurAxon, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.